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Abstract
The incidence of oesophageal adenocarcinoma has risen throughout the Western world over the last three dec-
ades. The prognosis remains poor as many patients are elderly and present with advanced disease. Those patients
who are suitable for resection remain at high risk of disease recurrence. It is important that cancer patients take
part in a follow up protocol to detect disease recurrence, offer psychological support, manage nutritional disorders
and facilitate audit of surgical outcomes. Despite the recognition that regular postoperative follow up plays a key
role in ongoing care of cancer patients, there is little consensus on the nature of the process. This paper reviews
the published literature to determine the optimal timing and type of patient follow up for those after curative
oesophageal resection.
Introduction
The incidence of adenocarcinoma of the oesophagus
and gastric cardia has been increasing throughout the
Western world over the last three decades while the
incidence of squamous cell carcinoma has remained
stable [1]. The prognosis is poor as many patients are
elderly and present with advanced disease making them
unsuitable for curative resection. The five-year survival
for all patients is less than 15% [2].
Surgery remains the primary curative treatment for
oesophageal adenocarcinoma, providing permanent relief
of dysphagia and offering the possibility of cure. A
recent compilation of the world literature by Jamieson
et al reported overall five-year survival rates in Western
countries of up to 30% in those undergoing curative
resection [2]. These results represent an improvement
from previous decades and can be attributed to preo-
perative staging investigations, better assessment of
operative risk improved operative techniques and better
perioperative management. Today in most large Eur-
opean oesophagogastric units mortality rates are less
than 5% [3,4]. The National Oesophagogastric Cancer
Audit in England and Wales covering 93% of all resec-
tional units recently reported an in-hospital mortality
rate of 5.0% following oesophagectomy [5]. Reductions
in postoperative mortality, whilst possibly improving
one year survival rates, do not translate into an
improvement for long term survival as many patients
continue to present with recurrent disease following
apparently curative surgery. A study by Mariette showed
that almost 50% of recurrent disease develops within
two years and this is within a group which has been
highly selected as resectable [6]. Studies have shown
that T stage, N status, lymph node ratio and complete-
ness of resection (R status) are important prognostic
factors in survival post oesophagectomy [7-11].
In order to provide the best quality of care to patients
who have undergone curative resection, clinical follow
up is recommended. This allows the clinician to detect
and treat benign complications of their treatment, detect
recurrent or metastatic disease, assess and manage
nutritional disorders, provide psychosocial support to
patients and their families and facilitate auditing of sur-
gical outcomes [12].
Despite the recognition that regular postoperative fol-
low up plays a key role in ongoing care of cancer
patients, there is little consensus on the nature of the
process.
This paper aims to review the published literature to
determine the optimal timing and type of patient follow
up and the nature of investigations to be performed.
Literature Search
A literature search was performed using Medline,
Embase and Cochrane databases searching for English
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literature available since 1975. The search was per-
formed with MESH terms “oesophageal cancer”, “adeno-
carcinoma of gastro-oesophageal junction”, “follow up
guidelines”, “disease recurrence”, “clinical practice guide-
lines”, “prognosis” and “survival”. All related articles
were examined. Where evidence was lacking for oeso-
phagogastric cancer follow up, the literature on other
common cancers such as breast and colon was
examined.
Results
Despite the recognition that regular postoperative follow
up plays a key role in the ongoing care of cancer
patients, there is little consensus on the nature of the
process and this is reflected in the lack of scientific data
in the literature. There are no randomised controlled
trials or other studies or series assessing the appropriate
follow up protocol for patients after curative oesophago-
gastric resection.
Published guidelines
There are four sets of guidelines available in the litera-
ture concerning the follow up of patients after curative
oesophagogastric resection - the British Society of Gas-
troenterology 2002, the Scottish Intercollegiate Guide-
lines Network (SIGN) 2006, the European Society of
Medical Oncology 2009 and the National Comprehen-
sive Cancer Network (NCCN) 2009 [12-15]. As stated,
there are no randomised controlled trials which specifi-
cally investigate the duration and frequency of follow
up. In all cases, adenocarcinoma of the distal oesopha-
gus and the gastroesophageal junction are regarded as
similar. A recent study has shown there is no difference
in surgical management, survival or recurrence between
these two tumours so their follow up should be
regarded as the same [16].
The main points from the guidelines demonstrate a
lack of defined or standardised follow up protocols. All
the guidelines admit that routine follow up does not
impact on patient survival outcomes but should be used
to concentrate on palliating symptoms from benign
complications of treatment, nutritional status and psy-
chosocial support. Studies have shown that cancer
patients prefer regular follow up for ongoing support
and reassurance and as a point of contact should new
symptoms or concerns arise [14,17,18]. It is important
to differentiate between those patients who are essen-
tially asymptomatic or have minor chronic symptoms in
whom a routine follow up approach is appropriate, and
those patients developing new or suspicious symptoms
in whom more urgent assessment and investigation is
required.
The following points will be briefly discussed: the
personnel involved in follow up protocols, the
investigations performed, the cost effectiveness of inten-
sive programmes, the effect of follow up on quality of
life and the treatment options available when recurrence
occurs.
Personnel involved in follow up
The guidelines suggest that follow up should be coordi-
nated within a multidisciplinary team involving the
patient, surgeon, oncologist, radiation oncologist, specia-
list nurse and dietician. The BSG guidelines suggest that
clinical nurse specialists could have a developed role in
the routine review of cancer patients, thus reducing the
need for medical based reviews in those patients who
are well. This would allow medical staff to focus on
those who need further input or investigation [12]. This
system is used successfully in follow up programmes of
other cancers [19,20].
Many patients prefer continued care in the primary
care setting, avoiding the stress of hospital visits, so rou-
tine follow up visits could be shared between the hospi-
tal clinic and the primary care setting. General
practitioners embarking on follow up will be only those
willing to undertake the work and there must be good
and rapid communication lines between the surgical
team and the primary care physician.
Frequency of follow up visits
There is little consensus in the literature regarding the
frequency of follow up visits. Many of the follow up
protocols used in the literature are fairly rigorous and
are often part of clinical trials looking at postoperative
outcomes such as disease recurrence and survival in
patients undergoing potentially curative resection.
The literature search was expanded to include trials
concerning follow up of common cancers such as breast,
lung and colorectal. There are several randomised con-
trolled trials examining the effects of intensive versus
non intensive follow up for these common cancers. The
American Society of Clinical Oncology breast cancer fol-
low up guidelines have shown no significant survival
advantage with an intensive surveillance protocol instead
of a clinically based protocol [21]. There is no consensus
regarding the follow up of patients after curative resec-
tion for colorectal cancer. The British Society of Gastro-
enterology guidelines suggest there is no evidence that
frequent follow up visits carry significant survival advan-
tages or benefits to patients whereas other meta-analyses
have shown some survival benefit as metachronous
tumours can be diagnosed earlier [22,23]. However these
tumours have completely different biology and treatment
options compared with oesophagogastric tumours, so
recommendations regarding the follow up of these can-
cers while providing a useful framework may not be
transferable to oesophagogastric cancer patients.
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The recurrence rate after oesophagogastric resection is
high (34-79%) with more than half recurring within the
first year and most presenting within two years of sur-
gery [24-26]. Mariette showed that 45.7% patients devel-
oped recurrence within 12 months of the operation, and
the time from recurrence to death was 7 months [6]. De
Manzoni confirmed similar results with 80% patients
undergoing potentially curative resection developing
recurrence within 24 months [7]. The depth of tumour
invasion (T stage) and number of positive lymph nodes
(N stage) are the main factors predictive of recurrent
disease after R0 resections [11,26]. The literature sug-
gests that patients with lymphovascular invasion, posi-
tive resection margins and high lymph node ratio have
poorer outcomes, but at present there is no evidence
that these factors are used in any follow up protocol or
to focus follow up [27-29].
Based on these patterns of recurrence, many units
recommend an initial postoperative visit four to six
weeks after surgery to check on wounds, nutritional sta-
tus and record any early complications from treatment.
Thereafter most centres vary between additional visits at
three to four month intervals for the first year, six
monthly reviews the second year, and annually there-
after [6-8,30-32]. Patients tend to be followed up for five
years but there is no evidence supporting this besides
the fact that most recurrences occur within this time.
Investigations performed
The SIGN guidelines state “no evidence has been identi-
fied to support regular imaging or measurement of
serum tumour markers in the follow up of patients with
gastroesophageal cancer outside clinical trials” [13].
However there are numerous different imaging proto-
cols used throughout Europe and North America.
Many patients have routine serum biochemistry per-
formed at each visit, and some centres measure carci-
noembryonic antigen (CEA) as a tumour marker which
can rise in the presence of recurrent disease. This is not
universal and studies have shown that CEA for oesopha-
geal adenocarcinoma is not reliable [33] with sensitivity
rates for detecting recurrence between 19- 39% and spe-
cificity rates of 89%.
The investigations used by most centres for routine
follow up are gastroscopy and biopsy, USS of neck,
computed tomography (CT), positron emission tomo-
graphy (PET), combined CT-PET and CT/US guided
biopsy of any identified suspicious lesion. There is no
evidence to suggest endoscopic ultrasound should be
used for routine follow up, as CT provides comparable
results for assessing local recurrence [34,35]. Some units
perform an annual CT of the neck, chest and abdomen
and a gastroscopy although some prefer six monthly
intervals [6,7,16,31]. Other groups prefer investigation
only if there is a clinical indication as treatment options
for recurrent disease are limited and the prognosis poor
[30,32].
Combination PET-CT is now increasingly being used
to detect recurrent disease following surgical resection
[34,36]. PET-CT appears to be both sensitive and speci-
fic for diagnosing distant metastases and local recur-
rence [37]. PET-CT may be useful when there is
diagnostic doubt after other investigations. At present
there is little evidence in the literature to suggest that
PET-CT should be involved in routine follow up proto-
cols. There is some evidence that unsuspected recur-
rence can be identified in asymptomatic patients but it
difficult to be sure this is in the patients’ best interests.
Quality of Life
The argument against intensive follow up is that it may
not lead to true survival advantage but is purely due to
lead time bias. Earlier diagnosis therefore not only fails
to prolong life but may reduce the quality of life due to
increased anxiety resulting from earlier knowledge of an
inevitable death [38]. Clinicians’ concerns regarding
quality of life are often based on survival whereas
patients tend to be more concerned about fears of dis-
ability and financial or social consequences. Follow up
visits and additional investigations often cause tempor-
ary anxiety in 30% patients, although this is then
replaced with reassurance and optimism in the case of
negative results [39]. Most patients value follow up as
good news can improve their quality of life, but even in
cases of recurrent disease where there are often no
treatment options, patients appreciate the honesty and
time given to be with family and deal with their affairs
[40].
Meta-analyses and randomised controlled trials in
breast and colorectal cancer patients have identified no
difference between quality of life and emotional well
being in those involved in either an intensive or non
intensive follow up programme [41].
Cost effectiveness
There have been no trials assessing the cost effective-
ness of intensive follow up of patients after oesophago-
gastric resection as there have been with other common
cancers [23,41]. It is therefore difficult to present scien-
tific data supporting an intensive follow up programme
with investigation for asymptomatic patients to detect
disease recurrence particularly when there is no evi-
dence that earlier detection affects outcome. Intensive
follow up programmes with annual endoscopy and CT
in asymptomatic patients, with further investigations if
required are costly to the health service and do not
impact on patient survival and often cause anxiety while
awaiting the results. It seems sensible that investigations
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are performed in symptomatic patients so that treatment
of benign complications or palliative therapy for recur-
rent disease can be commenced. However routine inves-
tigation of an asymptomatic population in whom there
are rarely any curative treatment options available for
recurrent disease cannot be recommended.
Recurrence following curative surgery
Cancer recurrence is a common problem after oesopha-
gectomy for oesophageal cancer. The mode of recur-
rence is often classified into three patterns: local
recurrence occurs at the anastomosis, regional recur-
rence in the mediastinum or upper abdomen at the site
of previous oesophageal resection, and distant recur-
rence defined as disease in other organs or peritoneum
[6,7]. Most recurrences occur within two years of sur-
gery. The median survival rate following regional recur-
rence was 7 months while patients with local or distant
disease have survival rates of only 5 months.
For many years there has been debate surrounding the
most appropriate resection for adenocarcinomas of the
mid and lower oesophagus. Most studies suggest that
while there may be a modest early survival advantage in
those undergoing a transhiatal approach, the long term
survival advantage does not seem to be affected accord-
ing to approach [42-45]. One study did report lower
recurrence rates and improved survival with the trans-
hiatal approach but this has not been supported by
other studies [46]. A recent follow up study assessing
five year survival rates in a large cohort of cancer
patients undergoing transhiatal and transthoracic oeso-
phagectomy concluded no difference in recurrence rates
or overall survival between the two groups. However
they suggest a transthoracic approach may be more
appropriate in those with between one and eight posi-
tive nodes as this offers a 41% increase in five year sur-
vival [47].
Treatment of recurrent disease
Patients presenting with disease recurrence may be
asymptomatic, the recurrent disease being identified on
routine surveillance, or symptomatic with dysphagia,
pain, weight loss or early satiety. Treatment options for
locally recurrent oesophageal cancer are limited. Reo-
peration for resection of locally recurrent oesophageal
disease is technically challenging as the approach is
made more difficult by the presence of scar tissue, and
the operative field has probably been previously irra-
diated. A study by Schipper et al analysed the outcome
of 23 patients who underwent re-resection of locally
recurrent disease [48]. Approximately one third were
found to have unresectable disease intraoperatively.
Two, three and five year survival rates for patients with
R0 re-resections were 62%, 44% and 35% respectively.
The authors conclude that re-resection of locally
advanced disease is associated with considerable mor-
bidity (59% complication rate and 7% operative mortal-
ity) but long term survival is possible in those
undergoing complete re-resection. However this is only
possible in a small minority of carefully selected
patients.
Therefore, for the majority of patients palliative thera-
pies become the mainstay of treatment, ensuring the
best quality of life and symptom control. Palliative
therapies for recurrent disease include radiation therapy,
chemotherapy, endoscopic interventions and a combina-
tion of these. Endoscopic stenting remains the most
popular method for alleviation of dysphagia although
other endoscopic treatments such as laser treatment,
photodynamic therapy and argon plasma coagulation
can be used. These treatments are useful for smaller
areas of recurrence and provide good symptomatic
relief, although repeated treatments are often required
to maintain symptom control. To date the optimal
endoscopic intervention for palliation of dysphagia has
not been established with a systematic review showing
no difference between the various endoscopic therapies
[49]. The choice of endoscopic treatment will depend
upon the endoscopist’s experience, the individual patient
and their pathology and the available resources in the
endoscopy unit.
Radiation treatment, either external beam radiotherapy
or intraluminal brachytherapy, allows high dose of radia-
tion to be delivered directly to the luminal surface of the
tumour. Studies have shown that brachytherapy is as
effective as stenting for the palliation of dysphagia.
Chemotherapy remains an option for the palliation of
recurrent and metastatic oesophagogastric cancer,
although there is limited evidence regarding its benefit.
It is often used in conjunction with other therapies, par-
ticularly radiotherapy. Although there may be a survival
advantage associated with chemotherapy, patients need
to attend regular hospital visits and the regimens can be
associated with significant side effects. These factors
may reduce the quality of the time patients have left
[50].
Discussion
The ideal follow up strategy should offer regular clinical
visits and where appropriate, focused investigation to
detect disease recurrence and offer support, but not so
frequently as to cause undue anxiety and harming their
quality of life.
The goals of patient follow up are to treat benign
complications which have arisen from surgery such as
anastomotic strictures and delayed gastric emptying
requiring endoscopic dilatation which tend to present
within the first year following surgery [51]. All patients
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should undergo nutritional assessment before and after
surgery and a dietician must be involved in each
patient’s care. Weight loss is a concerning symptom but
immediately following surgery this may be simply due to
inadequate caloric intake and adaptation of eating
habits. A further goal of follow up is to offer and main-
tain psychosocial support. Some patients will need more
support than others and the clinical nurse specialist
plays an invaluable role in this area. Follow up plays a
role in identifying disease recurrence as early as possible
to ensure patients receive the appropriate palliation or
further treatment if indicated. Finally it is imperative
that physicians record their morbidity, recurrence and
survival rates so we can continually endeavour to audit
and improve the management of these patients.
We would suggest the following as a possible follow
up strategy, as illustrated in Table 1, for clinically well
patients undergoing curative oesophagogastric resection
based on current practice, guidelines and typical peaks
of recurrence. This is by no means wholly evidence
based, but a pragmatic approach must be adopted in
order to provide patients with the reassurance and sup-
port they require, while being able to investigate and
manage symptoms as they present in order to ensure
the best quality of life for patients. Any symptomatic
patient needs directed investigations, most units starting
with either gastroscopy or CT neck, chest and abdomen.
Patients should undergo an initial postoperative check
within four weeks of discharge to rule out any immedi-
ate wound complications, discuss pathology results and
any further treatment if required, to identify nutritional
problems and discuss any unresolved issues. The rest of
the follow up should be focused on nutritional and psy-
chosocial support and identifying any concerning symp-
toms - all of these issues tending to arise within the first
two years after resection. Any patient developing recur-
rence can have their symptoms palliated efficiently and
appropriate support offered.
Patients should be assessed clinically with a history
and physical examination at three monthly intervals in
the first year and six monthly in the second year. An
annual clinical review should be performed for years
three, four and five years at which point the patient is
discharged back to the primary care team. The NCCN
guidelines which are widely used in the US advocate a
similar hospital based follow up programme. For some
patients who are highly motivated, and have a willing
primary care team, there may be a role of annual follow
up under the care of their general practitioner after year
2 with back to the surgical or oncological team if any
new issues arise. However we suspect the majority of
general practitioners, surgeons or patients may prefer
follow up under the surgeons who know the specifics
about their operative history and therefore hospital fol-
low up would be appropriate. Where the follow up visit
is in hospital, there should be a multidisciplinary
approach to avoid duplication of examinations and
investigations, and inconvenience to patients [12]. Clini-
cal investigations should only be performed if any speci-
fic new symptom develops.
Prediction of disease recurrence
As over 50% patients develop some form of recurrence,
predicting which patients are most likely to recur would
be of value. This clearly would have most impact in the
preoperative period ensuring appropriate en bloc resec-
tion and adjuvant therapy to reduce the risk of recur-
rence. At present, intensive postoperative follow up
strategies that pick up earlier asymptomatic recurrence
have no impact on overall survival - so it may not be
worth the cost and effort, and potential upset to the
patient. The TNM staging system is currently used in
assessing patients preoperatively and planning their
management. However a recent revision to the TNM
staging classification for oesophageal adenocarcinoma
has shown a new N classification based on the number
and location of the involved lymph nodes improves the
prognostic power [52]. The revised classification of
nodes (N0, none: N1, one to five: N2, six or more) was




1 4 weeks • Post operative wound check
• Assessment of nutritional status
• Discussion of pathology results
• Referral for further treatment
2 3 months • Nutritional assessment
• Identification of benign complications
3 6 months • As above
4 9 months • As above
5 12 months • As above
6 18 months • As above
7 24 months • Final assessment of general health
• If remains well, discharge back to GP
• Open access to surgical/oncology team if any
new concerning symptoms
8 36 months • Hospital clinic visit (or GP if preferred)
9 48 months • Hospital clinic visit (or GP if preferred)
10 60 months • Hospital clinic visit (or GP if preferred)
Any time • Development of new symptoms require
○ Assessment
○ Investigation - Initial CT chest/abdomen/
pelvis and endoscopy with further
investigation as clinically indicated (PET-CT,
bone scan, US)
○ Palliative therapies and care team
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prognostically significant when applied to 313 patients
undergoing oesophagectomy with curative intent. The
revised classification seems to stage individual patients
more accurately and may alter postoperative treatment
regimens and follow up.
A group from the Netherlands have developed a prog-
nostic normogram to aid prediction of disease specific
survival after oesophagectomy which seems to be super-
ior to TNM staging. However at present the normogram
estimates prognosis only after resection but the authors
feel it may be clinically helpful in providing more reli-
able prognostic information and in time tailor follow up
protocols [53].
There is much in the literature over the past few
years concerning the role of the systemic inflammatory
response and its relationship to cancer outcomes.
Studies have shown that those patients with increased
pre-treatment levels of C-reactive protein are more
likely to have poorer survival [54]. A Japanese group
suggest that those with increased CRP levels are at
higher risk of disease recurrence, while Deans and col-
leagues have suggested that CRP incorporated into a
clinical prognostic scoring system may aid the MDT
decision making process [55,56]. The benefit of this
scoring system over conventional pathological factors is
that the four variables (clinical stage, performance
score, weight loss and serum CRP concentration) can
be used prospectively to guide decisions at the time of
initial diagnosis, and give realistic prognostic informa-
tion. This could stratify patients into high risk groups,
requiring closer follow up.
Artificial neural networks, the combination of molecu-
lar markers and tumour and patient factors, can predict
outcomes from oesophageal cancer. A preliminary
model incorporating 199 variables in more than 400
oesophageal cancer patients has been developed which
may be more suitable than the TNM staging system in
classifying an individual’s patient recurrence risk and
survival [57].
Conclusions
There is no consensus in the literature regarding the
frequency, duration and imaging modalities used in the
follow up of patients undergoing curative resection for
oesophageal cancer. The clinical importance of follow
up for detection of recurrence at an early stage is
unclear, because there is no evidence that early detec-
tion of recurrence results in good treatment outcome.
The aim of follow up should be to provide patients
with the best quality of life by providing reassurance
and dealing with new symptoms as they arise. Over
investigation causes anxiety and we suggest appropriate
investigations should be used at the discretion of the
clinician when new symptoms arise. Based on the
limited evidence currently available, a five year hospital
based clinical follow up programme for patients under-
going curative oesophagogastric resection with transfer
back into the primary care sector seems a reasonable
strategy for patients who are well. However there may
be some patients who would prefer annual follow up for
years 3-5 under the care of their general practitioner,
which may be feasible provided rapid communication
links are open between primary and secondary health-
care systems. Urgent referral is required for any patient
developing new or worrisome symptoms. New strategies,
clinical prognostic scoring models and tumour markers
may be of benefit in the future.
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